July 28, 2017

Top Atrial Fibrillation (Afib) Articles of 2012

StopAfib.org is pleased to unveil the Top Ten Atrial Fibrillation Articles of 2012. There were many topics of interest this year to the atrial fibrillation patient community. As always, the top interest was atrial fibrillation stroke prevention — that included the CHADS2 and CHA2DS2-VASc scoring tools that determine the need for anticoagulants, the HAS-BLED tool […]

Do you have atrial fibrillation? Your input can help shape research to benefit afib patients.

Patients with atrial fibrillation are at higher risk of suffering stroke and other complications related to the development of blood clots in their heart. Until 2010, the only oral anticoagulant (blood thinner) to prevent strokes in Afib was warfarin (Coumadin®). Now there are two new oral anticoagulants available in the United States–dabigatran (Pradaxa®) and rivaroxaban […]

Atrial Fibrillation & Stroke Prevention–StopAfib.org interviews Dr. Daniel Singer

StopAfib.org interviews Dr. Daniel Singer, of Harvard Medical School. Find more information on this topic, Dr. Singer, and a transcript of the interview, at: http://stopafib.org/newsitem.cfm/NEWSID/394 In this video interview, Dr. Singer discussed topics covered in the stroke prevention in atrial fibrillation symposium he moderated at the Boston AF Symposium 2011. The topics discussed included the […]

Update on Atrial Fibrillation Stroke Prevention — Video interview with Dr. Daniel Singer of Harvard

In this interview, Dr. Daniel Singer updates us on the new anticoagulants for atrial fibrillation stroke prevention that he presented about at Boston Atrial Fibrillation Symposium. He provided an update on rivaroxaban (Xarelto), apixaban (Eliquis), dabigatran (Pradaxa), and edoxaban, and mentioned that all were better than warfarin (Coumadin) in preventing intracranial bleeding (bleeding in the […]

Atrial Fibrillation & Anticoagulants–StopAfib.org interviews Dr. Elaine Hylek

StopAfib.org interviews Dr. Elaine Hylek of Boston University. A transcript of this video, as well as additional information about the topics discussed, and Dr. Hylek, can be found at: http://www.stopafib.org/newsitem.cfm/NEWSID/349 In this video interview, Dr. Elaine Hylek of Boston University discusses new anticoagulant drugs for stroke prevention in atrial fibrillation. For many years, warfarin (Coumadin) […]

Top Atrial Fibrillation (Afib) Articles of 2011

In follow up to our announcement yesterday of the Top Ten Atrial Fibrillation Videos of 2011, StopAfib.org now unveils the Top Ten Atrial Fibrillation Articles of 2011. Major topics of interest to the atrial fibrillation patient community this year were afib stroke prevention and the CHADS2 and CHA2DS2-VASc scoring tools that determine the need for […]

Top Atrial Fibrillation (Afib) Videos of 2011

StopAfib.org has announced the Top Ten Atrial Fibrillation Videos of 2011. Afib stroke prevention again topped the list, with stories about warfarin (Coumadin), alternatives such as dabigatran (Pradaxa) and rivaroxaban (Xarelto), and the CHADS2 and CHA2DS2-VASc scoring tools for determining whether anticoagulants are needed. Other popular topics included sleep apnea, catheter ablation, and maze procedures (surgical […]

FDA Approves Alternative to Warfarin — Rivaroxaban (Xarelto) Approved for Atrial Fibrillation Stroke Prevention

The US Food and Drug Administration has approved Xarelto (rivaroxaban) to reduce stroke risk in those with non-valvular atrial fibrillation (afib unrelated to heart valve problems). Xarelto is now the second oral alternative to warfarin (Coumadin) and offers an option for those unable to take warfarin or dabigatran. Xarelto is the first once-a-day alternative to […]

Breaking News: FDA Panel Recommends Approval of Rivaroxaban (Xarelto) for Atrial Fibrillation Stroke Prevention

The US Food & Drug Administration (FDA) Advisory Committee just voted 9-2, with 1 abstaining, to recommend that the FDA approve rivaroxaban (Xarelto) for prevention of atrial fibrillation strokes. See our full story, now up at: FDA Panel Votes for Rivaroxaban: Atrial Fibrillation Patients May Soon Have Two Alternatives to Warfarin for Stroke Prevention

Rivaroxaban (Xarelto) Effective for Atrial Fibrillation Patients with High Stroke Risk

Just ahead of the FDA Advisory Committee hearing on rivaroxaban for stroke prevention in atrial fibrillation, we report in more depth on the ROCKET-AF trial results published recently in the New England Journal of Medicine. Rivaroxaban was shown to be as effective as warfarin (Coumadin) for stroke prevention in a high-risk afib population. To learn […]